Page 1 of 4
1234

Ambrose C, Jiang X, Mavunda K. The prevalence of diagnosed chronic lung disease in US infants by gestational age: Implications for RSV policy. ID Week, San Francisco, California, October 4, 2018.

Fryzek JP, Bylsma LC, Nordyke RJ, Sorensen HT. Rare disease epidemiology: A Danish population-based program. Poster presented at National Organization for Rare Disorders’ Rare Disease and Orphan Products Breakthrough Summit, Washington, D.C., October 2018.

Bylsma LC, Fryzek JP, Cetin K, Callaghan F, Bezold C, Mehta B, Wasser JS. 2018. Systematic literature review of treatments used for adult immune thrombocytopenia (ITP) in the second-line setting. Am J Hematol 94(1):115.

View Abstract

Czerkies LA, Kineman BD, Cohen SS, Reichert H, Carvalho RS. 2018. A pooled analysis of growth and tolerance of infants exclusively fed partially hydrolyzed whey or intact protein-based infant formulas. Int J Pediat Article ID 4969576.

View Abstract

Bylsma LC, Gulbech Ording A, Froslev T, Mehnert F, Fryzek J, Morales Arias J, Roth A, Sorensen HT, Berentsen S. Occurrence, survival, and thromboembolic risk in cold agglutinin disease: a population-based cohort analysis. Presented at the 23rd Congress of the European Hematology Association, June 14-17 2018, Stockholm, Sweden.

Ruzin A, Pastula ST, Levin-Sparenberg E, Jiang X, Fryzek J, Tovchigrechko A, Lu B, Qi Y, Liu H, Jin H, Yu L, Hackett J, Villafana T, Esser MT. 2018. Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States. PLoS One 13(7):e0200319.

View Abstract

Bylsma LC, Gulbech Ording A, Froslev T, Mehnert F, Fryzek JP, Morales Arias J, Roth A, Sorensen HT, Berentsen S. Occurrence, survival, and thromboembolic risk in cold agglutinin disease: a population-based cohort analysis. Presented at the 23rd Congress of the European Hematology Association, June 14-17 2018, Stockholm, Sweden.

Jensen IS, Wu E, Sacks NC, Cyr PL, Chung KC. 2018. Budget impact analysis of using daunarubicin-cytarabine liposome in patients with newly diagnosed therapy-related AML or AML and myelodysplasia-related changes. Am Health Drug Benefits 11(7):380–386. PMID: 30647825.

View Abstract

Beebe-Dimmer JL, Ruterbusch JJ, Bylsma LC, Gillezeau C, Fryzek J, Schultz NM, Flanders SC, Barlev A, Heath E, Quek RGW. 2018. Patterns of bicalutamide use in prostate cancer treatment: A U.S. real-world analysis using the SEER-Medicare database. Adv Ther 35(1):1438-1451.

View Abstract

Hooda N, McFarlane T, Pasetka M, DeAngelis C. 2018. Investigating guideline-consistent anti-emetic prescribing practices at the Odette Cancer Centre (OCC). Poster for oral presentation seminar, “Meet the Future Leaders in Research,” at the Ontario Pharmacist Conference, Huntsville, ON, June 2018.

Page 1 of 4
1234